# US 2021/0079421 A1 · Methods to produce chimeric adeno-associated virus/bocavirus parvovirus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079421 A1
- Document ID: US20210079421A1
- Status: Published application
- Kind: A1
- Application number: 16/076,219
- Filed: 2017-02-08
- Published: 2021-03-18
- Earliest claimed: 2016-02-08
- Assignees: University of Iowa Research Foundation; University of Kansas
- Applicants: University of Iowa Research Foundation; University of Kansas
- Inventors: Ziying Yan; John F. Engelhardt; Jianming Qiu
- Web page: https://patentgrep.com/patent/US20210079421A1

## CPC

- C07K 14/005: from viruses
- C12N 15/86: Viral vectors
- C07K 14/015: Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14145: Special targeting system for viral vectors
- C12N 2750/14322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C12N 2810/6027: ssDNA viruses
- C12N 2830/36: being a transcription termination element
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method of preparing a chimeric virus comprising bocavirus capsid protein (VP) and a recombinant adeno-associated (AAV) viral genome, and isolated mutant bocavirus genomes, are provided.

## Claims

### Claim 1

A method of preparing a chimeric virus comprising bocavirus capsid protein (VP) and a recombinant adeno-associated (AAV) viral genome, comprising:
a) providing a mutant bocavirus genome that when introduced to cells;
i) does not express one or more of bocavirus NS1, NS2, NS3 or NS4;
ii) expresses bocavirus VP1, VP2 and VP3; and
iii) expresses bocavirus NP1;
b) introducing the mutant bocavirus genome and a rAAV vector to cells which do not express one or more of bocavirus NS1, NS2, NS3 or NS4, thereby producing bocavirus VP, bocavirus NP1 and a rAAV genome; and
c) collecting chimeric rAAV/bocavirus.

### Claim 2 (depends on 1)

The method of claim 1 wherein the rAAV vector comprises an expression cassette encoding a heterologous gene product.

### Claim 3 (depends on 2)

The method of claim 2 wherein the gene product encodes a therapeutic protein.

### Claim 4 (depends on 1)

The method of claim 1 wherein the rAAV genome is a rAAV-1, rAAV-2, rAAV-3, rAAV-4, rAAV-5, rAAV-6, rAAV-7, rAAV-8 or rAAV-9 genome.

### Claim 5 (depends on 2)

The method of claim 2 wherein the gene product is a viral, bacterial, tumor, parasite, or fungal antigen.

### Claim 6 (depends on 2)

The method of claim 2 wherein the gene product is cystic fibrosis transmembrane conductance regulator, β-globin, γ-globin, tyrosine hydroxylase, glucocerebrosidase, aryl sulfatase A, factor VIII, dystrophin, alpha 1-antitrypsin, surfactant protein SP-D, SP-A or SP-C, C1 inhibitor gene, C1-INH gene, SERPING gene, erythropoietin, HBoV protein, influenza virus protein, RSV protein, a neutralizing antibody or an antigen binding fragment thereof, SARS virus protein, or a cytokine, e.g., IFN-alpha, IFN-gamma, TNF, IL-1, IL-17, or IL-6.

### Claim at position 7

7-8. (canceled)

### Claim 9

A method of preparing a chimeric virus comprising bocavirus capsid protein and a recombinant adeno-associated (AAV) viral genome which method is optionally independent of bocavirus NP1, comprising:
a) providing one or more vectors that express bocavirus VP1, VP2 and VP3 and express bocavirus NP1, but do not express one or more of bocavirus NS1, NS2, NS3 or NS4 or, if the method is independent of bocavirus NP1 providing a mutant bocavirus genome that when introduced to cells i) do not express any of, or expresses one or more of, bocavirus NS1, NS2, NS3 or NS4, and ii) expresses bocavirus VP1, VP2 and VP3, iii) do not express a functional bocavirus NP1, wherein the coding region for the one or more of the VP1, VP2 or VP3 in the mutant vector is codon optimized;
b) expressing the one or more vectors in cells that do not express one or more of bocavirus NS1, NS2, NS3 or NS4 and that have a rAAV vector of if the method is independent of bocavirus NP1, introducing the mutant bocavirus genome and a rAAV vector into cells that do not express bocavirus NP1 in trans, thereby producing bocavirus nonstructural proteins NS1, NS2, NS3 or NS4 capsid proteins and a rAAV genome; and
c) collecting chimeric rAAV/bocavirus virus.

### Claim at position 9

10-11. (canceled)

### Claim 12 (depends on 9)

The method of claim 9 wherein in the method that is independent of NP1 the rAAV vector comprises an expression cassette encoding a heterologous gene product.

### Claim 13 (depends on 12)

The method of claim 12 wherein the gene product encodes a therapeutic protein.

### Claim 14 (depends on 9)

The method of claim 9 wherein the rAAV genome is a rAAV-1, rAAV-2, rAAV-3, rAAV-4, rAAV-5, rAAV-6, rAAV-7, rAAV-8 or rAAV-9 genome.

### Claim 15 (depends on 9)

The method of claim 9 wherein the gene product is a viral, bacterial, tumor, parasite, or fungal antigen.

### Claim 16 (depends on 9)

The method of claim 9 wherein the gene product is cystic fibrosis transmembrane conductance regulator, β-globin, γ-globin, tyrosine hydroxylase, glucocerebrosidase, aryl sulfatase A, factor VIII, dystrophin, alpha 1-antitrypsin, surfactant protein SP-D, SP-A or SP-C, C1 inhibitor gene, C1-INH gene, SERPING gene erythropoietin, HBoV protein, influenza virus protein, RSV protein, a neutralizing antibody or an antigen binding fragment thereof, SARS virus protein, or a cytokine, e.g., IFN-alpha, IFN-gamma, TNF, IL-1, IL-17, or L-6.

### Claim 17 (depends on 9)

The method of claim 9 wherein the bocavirus is a human bocavirus.

### Claim 18 (depends on 9)

The method of claim 9 wherein in the method that is independent of bocavirus NP1 neither the cells nor the mutant genome provides for expression of any of bocavirus NS1, NS2, NS3 or NS4.

### Claim 19

A method of preparing a chimeric virus comprising bocavirus capsid protein and a recombinant adeno-associated (AAV) viral genome, which method is independent of bocavirus NP1, comprising:
a) providing one or more vectors that when introduced to cells i) do not express any of, or express one or more of, bocavirus NS1, NS2, NS3 or NS4, ii) express bocavirus VP1, VP2 and VP3, iii) do not express a functional bocavirus NP1, wherein the coding region for the one or more bocavirus VP1, VP2 or VP3 is codon optimized;
b) expressing the one or more vectors and a rAAV vector in cells that do not express NP1 in trans, thereby producing bocavirus nonstructural proteins NS1, NS2, NS3 or NS4 capsid protein and a rAAV genome; and
c) collecting chimeric rAAV/bocavirus.

### Claim 20 (depends on 19)

The method of claim 19 wherein the one or more vectors are integrated into the genome of the cell.

### Claim 21 (depends on 19)

The method of claim 19 wherein neither the cells nor the one or more vectors provides for expression of any of bocavirus NS1, NS2, NS3 or NS4.

### Claim 22 (depends on 1)

The method of claim 1 wherein the promoter that expresses bocavirus proteins is not a bocavirus promoter.

### Claim 23

An isolated mutant bocavirus genome that when introduced to cells i) does not express one or more of bocavirus NS1, NS2, NS3 or NS4; ii) expresses bocavirus VP1, VP2 and VP3; and iii) expresses bocavirus NP1; or a) expresses one or more of bocavirus NS1, NS2, NS3 or NS4; b) expresses bocavirus VP1, VP2 and VP3; and c) does not express a functional bocavirus NP1; or A) does not express any of bocavirus NS1, NS2, NS3 or NS4; B) expresses bocavirus VP1, VP2 and VP3; and C) does not express a functional bocavirus NP1.

### Claim at position 22

24-25. (canceled)

### Claim 26 (depends on 23)

The mutant genome of claim 23 wherein the promoter that expresses bocavirus proteins is not a bocavirus promoter.

### Claim at position 24

27-28. (canceled)
